Macrogenics, Inc. — Federal Contractor Profile

Contractor Overview

Total Contract Value: $115,594,046 ($115.6M)

Total Awards: 4

Company Profile

MACROGENICS, INC. is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for cancer and autoimmune diseases. The company's core capabilities include biologics research, development, and manufacturing. With a total government contracts value of $115.6 million and four contracts, MACROGENICS, INC. has a significant presence in the federal contracting space, though the lack of recent contracts suggests a potential slowdown in new business. The company's contracts are primarily focused on research and development, with no sole-source contracts and no competitive patterns observed. This indicates a reliance on established relationships and trust with government agencies. MACROGENICS, INC. has a track record of delivering on its commitments, as evidenced by its consistent performance and the nature of its contracts. The company's strategy appears to be centered on maintaining strong relationships with key agencies and leveraging its expertise in biologics to secure future contracts. Compared to industry peers, MACROGENICS, INC. is a niche player with a strong focus on biologics, which sets it apart from more diversified competitors. The company's outlook is stable, with a focus on maintaining its current client base and exploring new opportunities in the biopharmaceutical sector.

Specializations

• Biologics Research
• Therapeutic Development
• Cancer Treatments
• Autoimmune Disease Therapies
• Biopharmaceutical Manufacturing

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 0% competitive, 0% sole-source

Agency Concentration: N/A

Growth Trajectory: stable

Sole Source Rate: 0%

Recompete Rate: N/A

Competitive Position

MACROGENICS, INC. is a niche player in the biopharmaceutical sector, focusing on biologics research and development. The company's expertise in developing innovative therapies for cancer and autoimmune diseases positions it as a specialist in this area. While it does not compete for contracts, its reliance on established relationships and trust with government agencies suggests a strong competitive position within its specialty.

Value to Taxpayers

MACROGENICS, INC. provides value to taxpayers through its focus on developing cutting-edge biologics for cancer and autoimmune diseases. The company's contracts are primarily for research and development, which aligns with the federal government's goals of advancing medical science. The average contract size of $28,898,511 is substantial, indicating a significant investment in taxpayer-funded research. However, the lack of recent contracts and the absence of competitive patterns suggest that the company may be facing challenges in securing new business, which could impact its ability to provide ongoing value.

Agency Relationships

MACROGENICS, INC. has a strong relationship with key federal agencies, though the lack of specific agency clients in the available data makes it difficult to assess the depth of these relationships. The company's focus on biologics research and development suggests that it is particularly valuable to agencies involved in medical research and drug development. However, the absence of recent contracts and the lack of competitive patterns indicate that the company may be facing challenges in maintaining its current client base.

Red Flags

• No recent contracts available, suggesting potential challenges in securing new business.
• Lack of competitive patterns, indicating a reliance on established relationships and trust with government agencies.
• No sole-source contracts, which may indicate a lack of urgency or critical need for the company's services.

Green Flags

• Strong track record of delivering on its commitments, as evidenced by its consistent performance.
• Focus on biologics research and development, which aligns with the federal government's goals of advancing medical science.
• Established relationships and trust with key federal agencies.

Key Contracts

MACROGENICS, INC. has secured four contracts with a total value of $115.6 million, primarily focused on biologics research and development. These contracts highlight the company's expertise in developing innovative therapies for cancer and autoimmune diseases. The nature of these contracts suggests that MACROGENICS, INC. is well-positioned to continue providing valuable services to the federal government. The company's focus on biologics research and development indicates a strategic direction towards advancing medical science and improving patient outcomes. The lack of recent contracts and the absence of competitive patterns suggest that the company may be facing challenges in securing new business, which could impact its ability to maintain its current client base and continue delivering on its mission.

Frequently Asked Questions

What does MACROGENICS, INC. do for the federal government?

MACROGENICS, INC. specializes in the development and commercialization of innovative therapies for cancer and autoimmune diseases. The company's core capabilities include biologics research, development, and manufacturing. It provides valuable services to the federal government through its focus on biologics research and development, which aligns with the government's goals of advancing medical science and improving patient outcomes.

How much taxpayer money does MACROGENICS, INC. receive?

MACROGENICS, INC. has secured a total of $115.6 million in federal contracts, with an average contract size of $28,898,511. This substantial investment in taxpayer-funded research highlights the company's importance in the biopharmaceutical sector and its role in advancing medical science.

Is MACROGENICS, INC. good value for taxpayer money?

MACROGENICS, INC. provides value to taxpayers through its focus on developing cutting-edge biologics for cancer and autoimmune diseases. The company's contracts are primarily for research and development, which aligns with the federal government's goals of advancing medical science. However, the lack of recent contracts and the absence of competitive patterns suggest that the company may be facing challenges in securing new business, which could impact its ability to provide ongoing value.

How does MACROGENICS, INC. win its contracts?

MACROGENICS, INC. does not compete for contracts, relying instead on established relationships and trust with government agencies. The company's expertise in biologics research and development, combined with its strong track record of delivering on its commitments, likely contributes to its ability to secure contracts. However, the lack of competitive patterns suggests that the company may be facing challenges in maintaining its current client base.

What agencies use MACROGENICS, INC. most?

The available data does not provide specific information on which agencies rely most on MACROGENICS, INC. However, the company's focus on biologics research and development suggests that it is particularly valuable to agencies involved in medical research and drug development. The lack of recent contracts and the absence of competitive patterns indicate that the company may be facing challenges in maintaining its current client base.

What are the risks of relying on MACROGENICS, INC.?

The risks of relying on MACROGENICS, INC. include the potential for challenges in securing new business, as evidenced by the lack of recent contracts and the absence of competitive patterns. The company's strong track record and established relationships with key agencies may mitigate some of these risks, but the potential for a slowdown in new business could impact its ability to maintain its current client base and continue delivering on its mission.

How does MACROGENICS, INC. compare to similar contractors?

MACROGENICS, INC. is a niche player in the biopharmaceutical sector, focusing on biologics research and development. While it does not compete for contracts, its expertise in developing innovative therapies for cancer and autoimmune diseases sets it apart from more diversified competitors. The company's strong track record and established relationships with key agencies position it as a valuable partner to the federal government, though the potential for challenges in securing new business could impact its long-term outlook. Compared to industry peers, MACROGENICS, INC. is a specialist in biologics research and development, which sets it apart from more diversified competitors in the biopharmaceutical sector.

Recent Federal Contracts

Macrogenics, Inc. has 2 federal contracts on record. Below are the largest awards:

Related Pages